Disease burden of schizophrenia patients visiting a Chinese regional mental health centre-Reference-Cited by-同舟云学术

Disease burden of schizophrenia patients visiting a Chinese regional mental health centre

Published:2020-05 Issue:7 Volume:9 Page:469-481
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:Journal of Comparative Effectiveness Research

Author:

Zhong Qiuping¹²³⁴⁵,Tan Yuxi¹²³⁴⁵,Chen Wendong⁶⁷,Huang Huiqing⁶,Huang Jing¹²³⁴⁵,Li Sujuan¹²³⁴⁵,Teng Ziwei¹²³⁴⁵,Shen Manjun¹²³⁴⁵,Wu Chujun¹²³⁴⁵,Wang Lu¹²³⁴⁵,Cao Song¹²³⁴⁵,Chen Jindong¹²³⁴⁵,Wu Haishan¹²³⁴⁵,Tang Hui¹²³⁴⁵

Affiliation:

1. Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China

2. National Clinical Research Center on Mental Disorders (Xiangya), Changsha, Hunan, China

3. National Technology Institute on Mental Disorders, Changsha, Hunan, China

4. Hunan Key Laboratory of Psychiatry & Mental Health, Changsha, Hunan, China

5. Mental Health Institute, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China

6. Changsha Normin Health Technology Ltd, Changsha, China

7. Normin Health Consulting Ltd, Toronto, Ontario L5R 0E9, Canada

Abstract

Aim & methods: A decision-analytic model was constructed to simulate a real-world cohort of Chinese patients visiting a Chinese regional mental health center for long-term health outcomes and direct medical costs. Results: When compared with age and gender-matched general population, the Chinese patients with schizophrenia were associated with reduced overall survival by 20.6 years (27.6 vs 48.2 years) and reduced quality-adjusted life years (QALY) by 18.4 QALY (18.4 vs 36.8 QALY), respectively, and increased lifetime direct medical costs by about three-times (US$84,324 vs 33,387 as of 31 December 2017) on average. Conclusion: The burden of schizophrenia was mainly driven by the mortality associated with relapsed schizophrenia and direct medical costs for schizophrenia in local mental health rehabilitation institutes.

Publisher

Future Medicine Ltd

Subject

Health Policy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/cer-2019-0129

Reference29 articles.

1. Diagnostic and Statistical Manual of Mental Disorders

2. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010

3. National Institute for Clinical Excellence. Psychosis and schizophrenia in adults: prevention and management. National Clinical Practice Guidelines number CG178 (2014). www.nice.org.uk/guidance/cg178

4. The economic burden of mental disorders in China, 2005–2013: implications for health policy

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global prevalence of major depressive disorder in LGBTQ+ samples: A systematic review and meta-analysis of epidemiological studies;Journal of Affective Disorders;2024-09

2. A predictive model for readmission within 1-year post-discharge in patients with schizophrenia;BMC Psychiatry;2024-08-22

3. Relationship between medication burden and medication experience in stable patients with schizophrenia: the mediating effect of medication belief;BMC Nursing;2024-03-22

4. Increased serum homocysteine in first episode and drug-naïve individuals with schizophrenia: sex differences and correlations with clinical symptoms;BMC Psychiatry;2022-12-03

5. Increased serum homocysteine in first episode and drug-naïve patients with schizophrenia: Sex differences and correlations with pathophysiology;2022-08-08